Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic classification in myelodysplastic syndromes

G F Sanz1, P Morel

  • 1Service d'Hématologie, Hôpital Universitaire La Fe, Valence, Espagne.

Pathologie-Biologie
|May 7, 1998
PubMed
Summary

Prognostic scores for myelodysplastic syndromes (MDS) accurately predict outcomes using factors like bone marrow blasts and cytogenetics. However, these scores cannot identify patients who may not require treatment due to very long survival potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2019
Same author

Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation.

Transfusion medicine (Oxford, England)·2017
Same author

ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation.

Bone marrow transplantation·2016
Same author

Acute Promyelocytic Leukaemia. Relationship of Cytochemical Pattern with Clinical, Morphologic and Immunological Characteristics, and Outcome.

Leukemia & lymphoma·2016
Same author

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.

Bone marrow transplantation·2015

Area of Science:

  • Hematology
  • Oncology
  • Medical Prognostics

Background:

  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
  • Accurate prognosis is crucial for guiding treatment decisions in MDS patients.

Purpose of the Study:

  • To review the established prognostic factors for myelodysplastic syndromes (MDS).
  • To discuss the utility and limitations of current prognostic scoring systems in MDS.

Main Methods:

  • Review of established prognostic factors in myelodysplastic syndromes (MDS).
  • Analysis of bone marrow blast proportion, cytopenias, cytogenetic abnormalities, and molecular markers (e.g., RAS, p53 mutations).

Main Results:

  • Key prognostic factors include bone marrow blast percentage, severity of cytopenias, and cytogenetic abnormalities.

Related Experiment Videos

  • Prognostic scores integrating these factors offer high accuracy in predicting MDS outcomes.
  • Molecular markers like RAS and p53 mutations provide additional prognostic information.
  • Factors predicting therapeutic response largely overlap with those predicting survival.

    • Conclusions:

    • Current prognostic scoring systems for myelodysplastic syndromes (MDS) are effective but cannot identify all patients with favorable prognoses.
    • A subset of MDS patients with very long survivals may not require immediate treatment, highlighting a limitation of existing scores.